Cancer UrologyCancer UrologyОнкоурология1726-97761996-1812Publishing House ABV Press15310.17650/1726-9776-2011-7-2-39-45DIAGNOSIS AND TREATMENT OF URINARY SYSTEM TUMORS. URINARY BLADDER CANCERДИАГНОСТИКА И ЛЕЧЕНИЕ ОПУХОЛЕЙ МОЧЕПОЛОВОЙ СИСТЕМЫ. Рак мочевого пузыряUPPER URINARY TRACT TUMORS: 23-YEAR EXPERIENCE OF A CLINICОПУХОЛИ ВЕРХНИХ МОЧЕВЫВОДЯЩИХ ПУТЕЙ: 23-ЛЕТНИЙ ОПЫТ ОДНОЙ КЛИНИКИMatveevV. B.МатвеевВ. Б.
Russian Federation
asv2931@yandex.ruVolkovaM. I.ВолковаМ. И.
Russian Federation
asv2931@yandex.ruAfoninS. V.АфонинС. В.
Russian Federation
asv2931@yandex.ruRomanovV. A.РомановВ. А.
Russian Federation
asv2931@yandex.ruDepartment of Urology, N.N. Blokhin Russian Cancer Research Center, Russian Academy of Medical Sciences, MoscowОтделение урологии РОНЦ им. Н.Н. Блохина РАМН, Москва300620117239452907201429072014https://oncourology.abvpress.ru/oncur/article/view/153

The only factor that demonstrates its independent influence on overall survival in our series of observations is surgical radicality (p < 0.0001). This conclusion underlines the importance of the quality of surgical treatment for the prognosis of the disease. Surgical access and scope should be individually determined by the site, sizes, and hypothetical pathomorphological characteristics of a tumor. Correct choice of surgical tactics serves as a pledge to completely remove all afflicted tissues. The efficiency of neoadjuvant and adjuvant chemotherapy for pelvic and ureteral tumors has not been proven. The additional treatment has failed to affect survival in this study.

Единственный фактор, самостоятельное влияние которого на общую выживаемость показано в нашей серии наблюдений, – радикальность операции (р < 0,0001), это подчеркивает значимость качества хирургического лечения для прогноза пациентов. Хирургический доступ и операционный объем должны определяться индивидуально, исходя из локализации, размеров и предположительных патоморфологических характеристик опухоли. Правильный выбор хирургической тактики служит залогом полного удаления всех пораженных тканей. Эффективность неоадъювантной и адъювантной химиотерапии при опухолях лоханки и мочеточника не доказана. Результаты нашего исследования не подтвердили влияния дополнительного лечения на выживаемость.

tumors of the renal pelvis and ureterupper urinary tract neoplasmsопухоли почечной лоханки и мочеточникановообразования верхних мочевыводящих путей1. Park S., Hong B., Kim C.S., Ahn H. The impact of tumor location on prognosis of transitional cell carcinoma of the upper urinary tract. J Urol 2004;171:621–5.Park S., Hong B., Kim C.S., Ahn H. The impact of tumor location on prognosis of transitional cell carcinoma of the upper urinary tract. J Urol 2004;171:621–5.2. Badalament R.A., Bennett W.F., Bova J.G. et al. Computed tomography of primary transitional cell carcinoma of upper urinary tracts. Urology 1992;40:71–5.Badalament R.A., Bennett W.F., Bova J.G. et al. Computed tomography of primary transitional cell carcinoma of upper urinary tracts. Urology 1992;40:71–5.3. Streem S.B., Pontes J., Novick A.C. et al. Ureteropyeloscopy in the evaluation of upper tract filling defects. J Urol 1986;136:383–5.Streem S.B., Pontes J., Novick A.C. et al. Ureteropyeloscopy in the evaluation of upper tract filling defects. J Urol 1986;136:383–5.4. Michel K., Belldegrun A. Synchronous RCC and TCC of the Kidney in a Patient With Multiple Recurrent Bladder Tumors. Rev Urol 1999 Spring;1(2):99–103.Michel K., Belldegrun A. Synchronous RCC and TCC of the Kidney in a Patient With Multiple Recurrent Bladder Tumors. Rev Urol 1999 Spring;1(2):99–103.5. Murta C.B., Antunes A.A., Dall'Oglio M.F. et al. Analysis of the clinicopathological characteristics of patients with upper urinary tract transitional cell carcinoma. Clinics (Sao Paulo) 2008;63(2):223–8.Murta C.B., Antunes A.A., Dall'Oglio M.F. et al. Analysis of the clinicopathological characteristics of patients with upper urinary tract transitional cell carcinoma. Clinics (Sao Paulo) 2008;63(2):223–8.6. Charbit L., Gendreau M.C., Mee S. et al. Tumors of the upper urinary tract: 10 years experience. J Urol 1991;146:1243–6.Charbit L., Gendreau M.C., Mee S. et al. Tumors of the upper urinary tract: 10 years experience. J Urol 1991;146:1243–6.7. Fujii Y., Kawakami S., Koga F. et al. Long-term outcome of bladder papillary urothelial neoplasms of low malignant potential. BJU Int 2003;92:559–62. [PubMed]Fujii Y., Kawakami S., Koga F. et al. Long-term outcome of bladder papillary urothelial neoplasms of low malignant potential. BJU Int 2003;92:559–62. [PubMed]8. Canales B.K., Anderson J.K., Premoli J., Slaton J.W. Risk factors for upper tract recurrence in patients undergoing long-term surveillance for stage ta bladder cancer. J Urol 2006;175:74–7. [PubMed].Canales B.K., Anderson J.K., Premoli J., Slaton J.W. Risk factors for upper tract recurrence in patients undergoing long-term surveillance for stage ta bladder cancer. J Urol 2006;175:74–7. [PubMed].9. Sanderson K.M., Cai J., Miranda G. et al.Upper tract urothelial recurrence following radical cystectomy for transitional cell carcinoma of the bladder: an analysis of 1,069 patients with 10-year followup. J Urol 2007;177:2088–94. [PubMed]Sanderson K.M., Cai J., Miranda G. et al.Upper tract urothelial recurrence following radical cystectomy for transitional cell carcinoma of the bladder: an analysis of 1,069 patients with 10-year followup. J Urol 2007;177:2088–94. [PubMed]10. Miyake H., Hara I., Gohji K. et al. The significance of lymphadenectomy in transitional cell carcinoma of the upper urinary tract. Br J Urol 1998;82(4):494–8.Miyake H., Hara I., Gohji K. et al. The significance of lymphadenectomy in transitional cell carcinoma of the upper urinary tract. Br J Urol 1998;82(4):494–8.11. Kondo T., Nakazawa H., Ito F. et al. Impact of the extent of regional lymphadenectomy on the survival of patients with urothelial carcinoma of the upper urinary tract. J Urol 2007;178 (4 Pt 1):1212–7;discus 1217.Kondo T., Nakazawa H., Ito F. et al. Impact of the extent of regional lymphadenectomy on the survival of patients with urothelial carcinoma of the upper urinary tract. J Urol 2007;178 (4 Pt 1):1212–7;discus 1217.12. Roscigno M., Shariat S.F., Margulis V. et al. Impact of lymph node dissection on cancer specific survival in patients with upper tract urothelial carcinoma treated with radical nephroureterectomy. J Urol 2009;181(6):2482–9.Roscigno M., Shariat S.F., Margulis V. et al. Impact of lymph node dissection on cancer specific survival in patients with upper tract urothelial carcinoma treated with radical nephroureterectomy. J Urol 2009;181(6):2482–9.13. Rassweiler J.J., Schulze M., Marrero R. et al. Laparoscopic nephroureterectomy for upper urinary tract transitional cell carcinoma: is it better than open surgery? Eur Urol 2004;46(6):690–7.Rassweiler J.J., Schulze M., Marrero R. et al. Laparoscopic nephroureterectomy for upper urinary tract transitional cell carcinoma: is it better than open surgery? Eur Urol 2004;46(6):690–7.14. Ubrig B., Renner K., Fallahi M., Roth S. Are there indications for organ-preserving tumor resection in urothelial cancers of the upper urinary tract? Aktuelle Urol 2005;36(2):136–41.Ubrig B., Renner K., Fallahi M., Roth S. Are there indications for organ-preserving tumor resection in urothelial cancers of the upper urinary tract? Aktuelle Urol 2005;36(2):136–41.15. Lee S.E., Byun S.S., Park Y.H. et al. Adjuvant chemotherapy in the management of pT3N0M0 transitional cell carcinoma of the upper urinary tract. Urol Int 2006; 77(1):22–6.Lee S.E., Byun S.S., Park Y.H. et al. Adjuvant chemotherapy in the management of pT3N0M0 transitional cell carcinoma of the upper urinary tract. Urol Int 2006; 77(1):22–6.16. Advanced Bladder Cancer Metaanalysis Collaboration. Neoadjuvant chemotherapy in invasive bladder cancer: a systematic review and metaanalysis. Lancet 2003;361:1927–34.Advanced Bladder Cancer Metaanalysis Collaboration. Neoadjuvant chemotherapy in invasive bladder cancer: a systematic review and metaanalysis. Lancet 2003;361:1927–34.17. Hall M.C., Womack S., Sagalowsky A.I. et al. Prognostic factors, recurrence and survival in transitional cell carcinoma of the upper urinary tract: a 30-year experience in 252 patients. Urology 1998;52:594–601.Hall M.C., Womack S., Sagalowsky A.I. et al. Prognostic factors, recurrence and survival in transitional cell carcinoma of the upper urinary tract: a 30-year experience in 252 patients. Urology 1998;52:594–601.18. Novara G., De Marco V., Gottardo F. et al. Independent predictors of cancerspecific survival in transitional cell carcinoma of the upper urinary tract: multi-institutional dataset from 3 European centers. Cancer 2007;110(8):1715–22.Novara G., De Marco V., Gottardo F. et al. Independent predictors of cancerspecific survival in transitional cell carcinoma of the upper urinary tract: multi-institutional dataset from 3 European centers. Cancer 2007;110(8):1715–22.19. Guinan P., Vogelzang N.J., Randazzo R. et al. Renal pelvic cancer: a review of 611 patients treated in Illinois 1975–1985. Urology 1992;40:393–9.Guinan P., Vogelzang N.J., Randazzo R. et al. Renal pelvic cancer: a review of 611 patients treated in Illinois 1975–1985. Urology 1992;40:393–9.